扶正化痰方联合EGFR-TKI治疗晚期肺腺癌的疗效研究

doi:10.3760/cma.j.issn.1007-1245.2023.03.012

国际医药卫生导报 ›› 2023, Vol. 29 ›› Issue (3): 352-355.DOI: 10.3760/cma.j.issn.1007-1245.2023.03.012

扶正化痰方联合EGFR-TKI治疗晚期肺腺癌的疗效研究

苗健龙刘瑞娟

济宁市第一人民医院呼吸与危重症医学科，济宁　272000

收稿日期:2022-09-28 出版日期:2023-02-01 发布日期:2023-03-02
通讯作者: 刘瑞娟，Email：mjllf2000@126.com
基金资助:
山东省中医药科技发展计划项目（2017—416）

Effect of Fuzheng Huatan decoction combined with EGFR-TKI on patients with advanced lung adenocarcinoma

Miao Jianlong, Liu Ruijuan

Department of Respiratory Medicine, Jining No.1 People's Hospital, Jining 272000, China

Received:2022-09-28 Online:2023-02-01 Published:2023-03-02
Contact: Liu Ruijuan, Email: mjllf2000@126.com
Supported by:
TCM Science and Technology Development Program of Shandong Province (2017—416)

摘要/Abstract

摘要：

目的　分析扶正化痰方联合表皮生长因子受体-酪氨酸激酶抑制剂（EGFR-TKI）对晚期EGFR敏感突变肺腺癌患者的疗效，探讨扶正化痰方的增效减毒作用，评估该药对患者预后的影响。方法　选择济宁市第一人民医院自2017年7月至2019年12月初始治疗的ⅢB期或Ⅳ期肺腺癌伴EGFR敏感突变患者78例（治疗组40例、对照组38例）。其中男36例，女42例，年龄（60.65±12.12）岁，治疗前卡式功能状态量表（KPS）评分（63.84±15.30）分。治疗方案：对照组给予EGFR-TKI靶向药物治疗；治疗组给予靶向治疗联合扶正化痰方。观察指标：比较两组客观缓解率（ORR）、无疾病进展生存期（PFS）、KPS评分、不良反应。采用独立样本t检验、χ²检验、Fisher确切概率法、Kaplan-Meier法。结果　（1）疗效：两组患者ORR、PFS差异均无统计学意义［82.50%（33/40）比81.57%（31/38），（10.86±2.60）个月比（10.08±1.56）个月］（均P>0.05）。（2）不良反应：治疗组与对照组比较，肝损害、皮疹、腹泻、间质性肺炎、口腔黏膜炎发生率较低，但差异均无统计学意义（均P>0.05）。（3）治疗组KPS评分改善比例明显较对照组高［77.50%（31/40）比55.26%（21/38），P<0.05］。结论　扶正化痰方联合EGFR-TKI治疗晚期肺腺癌患者可提高患者生活质量，可能会减少不良反应的发生，但不能明显延长患者PFS。

关键词:

肺腺癌, EGFR, TKI, 扶正化痰方

Abstract:

Objective　To analyze the efficacy of Fuzheng Huatan decoction combined with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) in patients with advanced EGFR-sensitive mutant lung adenocarcinoma, to explore the synergistic and toxic attenuation effects of Fuzheng Huatan decoction, and to evaluate the influence of Fuzheng Huatan decoction on the patients' prognosis. Methods　This study selected 78 patients with stage IIIB or IV EGFR gene mutation lung adenocarcinoma in Jining No.1 People's Hospital from July 2017 to December 2019, who were divided into a control group (38 cases) and an observation group (40 cases). Among them, there were 36 males and 42 females, aged (60.65±12.12) years, and the Karnofsky Performance Status (KPS) score before treatment was (63.84±15.30). The observation group was given EGFR-TKI combined with Fuzheng Huatan decoction, and the control group was given EGFR-TKI only. The objective response rate (ORR), progression-free survival (PFS), KPS score, and adverse reactions were compared between the two groups. Independent sample t test, χ² test, Fisher exact probability method, and Kaplan-Meier method were used. Results　(1)There were no statistically significant differences in the ORR and PFS between the two groups [82.50% (33/40) vs. 81.57% (31/38), (10.86±2.60) months vs. (10.08±1.56) months] (both P>0.05). (2)Compared with those in the control group, the incidences of liver damage, rash, diarrhea, interstitial pneumonia, and oral catarrh in the observation group were lower, but the differences were not statistically significant (all P>0.05). (3)The improvement rate of KPS score in the observation group was significantly higher than that in the control group [77.50% (31/40) vs. 55.26% (21/38), P<0.05]. Conclusion　Fuzheng Huatan decoction combined with EGFR-TKI in the treatment of advanced EGFR mutant lung adenocarcinoma patients can improve their quality of life and may reduce the occurrence of adverse reactions, but can not significantly prolong their PFS.

Key words:

Lung adenocarcinoma, EGFR, TKI, Fuzheng Huatan decoction

苗健龙刘瑞娟.

扶正化痰方联合EGFR-TKI治疗晚期肺腺癌的疗效研究 [J]. 国际医药卫生导报, 2023, 29(3): 352-355.

Miao Jianlong, Liu Ruijuan.

Effect of Fuzheng Huatan decoction combined with EGFR-TKI on patients with advanced lung adenocarcinoma [J]. International Medicine and Health Guidance News, 2023, 29(3): 352-355.

参考文献

[1] 中华医学会肿瘤学分会,中华医学会杂志社.中华医学会肿瘤学分会肺癌临床诊疗指南(2021版)[J].中华肿瘤杂志,2021,43(6):591-621. DOI:10.3760/cma.j.cn112152- 20210207-00118.
[2] Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2012, National Cancer Institute. https://seer.cancer.gov/archive/csr/1975_2012/.
[3] Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study[J]. Lancet Oncol, 2011, 12(8):735-742. DOI: 10.1016/S1470-2045(11)70184-X.
[4] Wu YL, Zhou C, Liam CK, et al. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study[J]. Ann Oncol, 2015, 26(9):1883-1889. DOI: 10.1093/annonc/mdv270.
[5] Wu YL, Zhou C, Hu CP, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial[J]. Lancet Oncol, 2014, 15(2):213-222. DOI: 10.1016/S1470-2045(13)70604-1.
[6] Zhang X, Chang A. Molecular predictors of EGFR-TKI sensitivity in advanced non-small cell lung cancer[J]. Int J Med Sci, 2008, 5(4):209-217. DOI: 10.7150/ijms.5.209.
[7] 王超,李元滨.中药复方多靶点逆转肺癌化疗多药耐药机制效应的研究进展[J].中华中医药杂志,2019,34(2):688-691.
[8] 杨霖,王笑民,杨国旺,等.从"痰浊毒邪致病"探讨化痰排浊解毒法在原发性肺癌治疗中的意义[J].时珍国医国药,2019,30(2):433-434. DOI:10.3969/j.issn.1008-0805. 2019.02.061.
[9] 容国义,王淑美,唐末.中医化痰法治疗非小细胞肺癌疗效的Meta分析[J].中国临床药理学与治疗学,2017,22(7):787-794.
[10] 董明娥.六君子汤三子养亲汤联合介入治疗中晚期肺癌60例[J].陕西中医,2013,34(6):705-706. DOI:10.3969/j.issn.1000-7369.2013.06.044.
[11] 郑红刚,花宝金,朴炳奎.肿瘤扶正培本思想源流概述[J].中医杂志,2015,56(15):1269-1272. DOI:10.13288/j.11-2166/r.2015.15.003.
[12] 蒋树龙,花宝金.肿瘤发生发展痰瘀本质及其与肿瘤微环境关系探析[J].中国中医基础医学杂志,2015,21(11):1417-1419. DOI:10.19945/j.cnki.issn.1006-3250.2015. 11.032.
[13] 凌云霄,王建涛,王艳.放化疗性口腔黏膜炎相关生物标志物研究进展[J].口腔疾病防治,2021,29(4):260-266. DOI:10.12016/j.issn.2096-1456.2021.04.007.

扶正化痰方联合EGFR-TKI治疗晚期肺腺癌的疗效研究

Effect of Fuzheng Huatan decoction combined with EGFR-TKI on patients with advanced lung adenocarcinoma

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 0

编辑推荐

Metrics